We are live on !
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
Turnover
44%
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter Est. Return
+14.65%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$331M
AUM Growth
+$11.7M
(+3.7%)
Cap. Flow
-$38.1M
Cap. Flow % of AUM
Cap. Flow %
-11.51%
Top 10 Holdings %
Top 10 Hldgs %
42.42%
Holding
75
New
12
Increased
16
Reduced
23
Closed
21
Avg Time Held
Equity + Options
0.7
years
Top 10 Avg Time Held
Equity + Options
0.2
years
Top 20 Avg Time Held
Equity + Options
0.4
years
Avg Time Held Equity only
0.8
years
Top 10 Avg Time Held Equity only
0.2
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Novo Nordisk
NVO
|
+$14.7M |
| 2 |
Blueprint Medicines
BPMC
|
+$9.9M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$8.99M |
| 4 |
Janux Therapeutics
JANX
|
+$6.09M |
| 5 |
Dyne Therapeutics
DYN
|
+$3.98M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biohaven
BHVN
|
+$19.1M |
| 2 |
Viridian Therapeutics
VRDN
|
+$8.38M |
| 3 |
MoonLake Immunotherapeutics
MLTX
|
+$8.04M |
| 4 |
Soleno Therapeutics
SLNO
|
+$7.18M |
| 5 |
Vaxcyte
PCVX
|
+$6.31M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.31% |
| 2 | Miscellaneous | 16.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
aTyr Pharma
ATYR
$16.8M
| $1.41M | 0.43% |
800,000
| – | – |
2024 Q1
2 quarters
|
|
52
Larimar Therapeutics
LRMR
$220M
| $1.31M | 0.4% |
+200,000
| New | +$1.61M |
2024 Q3
0 quarters
|
|
53
enGene Therapeutics
ENGN
$106M
| $1.06M | 0.32% |
160,898
-259,433
| -62% | -$1.93M |
2024 Q1
2 quarters
|
|
54
Amylyx Pharmaceuticals
AMLX
$3.43B
| $1.05M | 0.32% |
+325,000
| New | +$731K |
2024 Q3
0 quarters
|
|
55
Acadia Pharmaceuticals
ACAD
$3.41B
| – | – |
-225,000
| Closed | -$3.66M | – |
|
56
Alnylam Pharmaceuticals
ALNY
$31.2B
| – | – |
-22,500
| Closed | -$5.47M | – |
|
|
57
PUT
Alnylam Pharmaceuticals
ALNY
$31.2B
| – | – |
-68,400
| Closed | -$16.6M | – |
|
58
CALL
Annexon
ANNX
$760M
| – | – |
-214,500
| Closed | -$1.05M | – |
|
59
AN2 Therapeutics
ANTX
$127M
| – | – |
-219,331
| Closed | -$472K | – |
|
60
Arrowhead Research
ARWR
$8.08B
| – | – |
-35,000
| Closed | -$910K | – |
|
|
61
Biohaven
BHVN
$1.71B
| – | – |
-490,000
| Closed | -$19.1M | – |
|
62
Cabaletta Bio
CABA
$251M
| – | – |
-370,899
| Closed | -$2.77M | – |
|
63
CytomX Therapeutics
CTMX
$510M
| – | – |
-300,000
| Closed | -$366K | – |
|
64
Cytokinetics
CYTK
$8.71B
| – | – |
-33,200
| Closed | -$1.8M | – |
|
65
DELISTED
Elevation Oncology
ELEV
| – | – |
-600,000
| Closed | -$1.62M | – |
|
66
Krystal Biotech
KRYS
$9.48B
| – | – |
-8,500
| Closed | -$1.56M | – |
|
67
MacroGenics
MGNX
$212M
| – | – |
-150,000
| Closed | -$638K | – |
|
68
Intellia Therapeutics
NTLA
$1.62B
| – | – |
-25,000
| Closed | -$560K | – |
|
69
PMV Pharmaceuticals
PMVP
$67.1M
| – | – |
-375,000
| Closed | -$608K | – |
|
70
PTC Therapeutics
PTCT
$5.14B
| – | – |
-19,000
| Closed | -$581K | – |
|
71
CALL
DELISTED
RAPT Therapeutics
RAPT
| – | – |
-37,500
| Closed | -$915K | – |
|
72
Sagimet Biosciences
SGMT
$628M
| – | – |
-225,000
| Closed | -$770K | – |
|
73
Wave Life Sciences
WVE
$625M
| – | – |
-200,000
| Closed | -$998K | – |
|
74
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| – | – |
-10,000
| Closed | -$685K | – |
|
75
DELISTED
Revance Therapeutics, Inc.
RVNC
| – | – |
-225,000
| Closed | -$578K | – |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q3 2024 Portfolio in Review
As of Q3 2024, Ghost Tree Capital held 75 positions worth $331M, up 3.7% from $319M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Ghost Tree Capital withdrew a net $38.1M in Q3 2024, closing 21 positions and reducing 23 holdings. Its most notable exit was Biohaven, an estimated $19.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 90% a quarter earlier, followed by Miscellaneous.
Against the trend, Ghost Tree Capital opened a new position in Novo Nordisk worth $13.1M.
- Ghost Tree Capital's largest Q3 2024 buy was Novo Nordisk: 110,000 shares worth $13.1M.
- Ghost Tree Capital added most to Blueprint Medicines in Q3 2024, an estimated $9.9M increase.
- Ghost Tree Capital's biggest Q3 2024 reduction was Viridian Therapeutics, cutting an estimated $8.38M.
- Ghost Tree Capital fully exited Biohaven in Q3 2024, selling an estimated $19.1M.
- Ghost Tree Capital's ten largest holdings make up 42% of its $331M portfolio in Q3 2024.
- Ghost Tree Capital opened 12 new positions and closed 21 in Q3 2024.
- Ghost Tree Capital's portfolio value rose 3.7% quarter-over-quarter to $331M.
Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.